Showing results (331-340 of 491) with videos related to

Sort By:
Pageof 50
Circulation|October 8, 2008
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular riskJohn W Eikelboom, Graeme J Hankey, Jim Thom, et al.
Open Heart|May 11, 2023
Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registryPatricia Apenteng, Saverio Virdone, John Camm, et al.
European Heart Journal|April 10, 2024
Invasive vs. conservative management of older patients with non-ST-elevation acute coronary syndrome: individual patient data meta-analysisChristos P Kotanidis, Gregory B Mills, Bjørn Bendz, et al.
Heart (British Cardiac Society)|May 22, 2021
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery diseaseGilles R Dagenais, Leanne Dyal, Jacqueline J Bosch, et al.
Heart Rhythm O2|August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AFFrancis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
Journal of the American College of Cardiology|February 27, 2016
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus ClopidogrelJacob A Doll, Megan L Neely, Matthew T Roe, et al.
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.
JAMA|July 3, 2008
Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysisMichelle O'Donoghue, William E Boden, Eugene Braunwald, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
Pageof 50